Ferrociphenols are known to display anticancer properties by original mechanisms dependent on redox properties and generation of active metabolites such as quinone methides. Recent studies have highlighted the positive impact of oxidative stress on chemosensitivity and prognosis of ovarian cancer patients. Ovarian adenocarcinomas are shown to be an excellent model for defining the impact of selected ferrociphenols as new therapeutic drugs for such cancers. This work describes the syntheses and preliminary mechanistic research of unprecedented multitargeting heterocyclic ferrociphenols bearing either a succinimidyl or phthalimidyl group that show exceptional antiproliferative behavior against epithelial ovarian cancer cells resistant to cisplatin. Owing to the failure of the present pharmaceutical options, such as carboplatin a metallodrug based on Pt coordination chemistry, these species may help to overcome the problem of lethal resistance. Currently, ferrociphenolic entities generally operate via apoptotic and senescence pathways. We present here our first results in this new cyclic-imide series.

中文翻译：

---

一系列新的琥珀酰亚胺基亚铁环酚和相关杂环物种具有较强的抗增殖作用，尤其是针对抗顺铂的卵巢癌细胞

已知亚铁酚通过依赖于氧化还原特性和活性代谢物例如醌甲基化物的产生的原始机理显示出抗癌特性。最近的研究强调了氧化应激对卵巢癌患者化学敏感性和预后的积极影响。卵巢腺癌被证明是一种很好的模型，可用于定义选定的亚铁氰酚作为此类癌症的新治疗药物的影响。这项工作描述了前所未有的具有琥珀酰亚胺基或邻苯二甲酰亚胺基团的多目标杂环亚铁氰基酚的合成和初步机理研究，这些亚铁氰基酚对顺铂耐药的上皮性卵巢癌细胞显示出优异的抗增殖行为。由于目前的药物选择不力，例如卡铂，一种基于Pt配位化学的金属药物，这些物质可能有助于克服抗药性的问题。当前，亚铁环酚类实体通常通过凋亡和衰老途径起作用。我们在这里展示了这个新的环状酰亚胺系列的第一批结果。